Organic insecticide poisoning continues to be a major health problem not only in the developing communities but also in the Western population. The insecticides commonly used are the organophosphates, organocarbamates, organochlorides and pyrethroids. Patients with organic insecticide poisoning present with a spectrum of manifestations ranging from gastrointestinal symptoms of nausea, vomiting and diarrhoea to severe neurological manifestations of fasciculations, seizures and neuromuscular weakness and paralysis or cardiac manifestations of arrhythmias and conduction disturbances. A strong clinical suspicion is necessary to make an early diagnosis of insecticide poisoning. Treatment is primarily supportive and includes decontamination, protection of airways and cardiac and respiratory monitoring. Specific therapy for organophosphates and organocarbamates includes the use of anticholinergics. The use of oximes, especially high dose, is controversial and may be associated with a higher mortality rate. Low-dose oximes given early in the course of the illness may be beneficial. This paper reviews the literature on organic insecticide poisoning worldwide.
Organic insecticides are compounds that have been used globally for pest control for over 100 years. These are common agents of suicidal or accidental poisoning, as a result of their ready availability and easy accessibility.
There are four classes of organic insecticides which act predominantly as neurotoxins. They include a) organophosphates, b) organocarbamates, c) organochlorides and d) pyrethroids.
ORGANOPHOSPHORUS INSECTICIDES
The organophosphorus (OP) compounds are the insecticides of choice in the agricultural world and are the most common cause of poisoning among the pesticides. The Environmental Protection Agency (EPA) at Washington reported that 80% of all hospitalizations from pesticide poisoning were due to the organophosphate group 1 . The American Association of Poison Control Centres indicated that organophosphorus compounds accounted for 33,000 of the 77,000 exposures to insecticides in 1983 2 . In a subsequent report approximately 5000 patients were treated yearly for exposure to organophosphorus compounds 3 . WHO estimates suggest that more than three million cases of acute serious pesticide poisoning occur worldwide annually, the majority being caused by organophosphates especially in the developing countries 4 .
In third world countries, organophosphorus poisoning is a major cause of morbidity and mortality and accounts for a large proportion of patients admitted to the intensive care units. At the Christian Medical College and Hospital, Vellore, India, it accounts for 12% of all ICU admissions and 29% of poisonings 5 . In another centre it accounted for 89.75% of the 107 patients admitted with poisoning 6 . In Pakistan it accounted for 39.7% of cases admitted with poisoning and 16% of total admissions to the ICU 7 . It is also a common suicidal agent in Sri Lanka 8,9 . The organophosphates are popular insecticides because of their effectiveness and lack of persistence in the environment due to their unstable chemical nature. Thus they do not persist in body tissues or the environment as do organochlorides and subsequently have replaced DDT as the insecticide group of choice 10 .
Ingestion of organophosphates in an attempt to commit suicide is a major problem in some communities. This problem appears to be more frequent in the developing countries probably because of the wide availability of pesticides as a result of extensive use in agricultural communities and because many such countries also allow the sale of organophosphates directly over the counter and have inadequate regulations controlling their use and storage.
Early and correct diagnosis and treatment may be life-saving in organophosphorus poisoning and a good understanding of the pathophysiology and clinical manifestations is essential for physicians
Historical Perspective
The first organophosphate synthesized in 1854, tetra-ethyl pyrophosphate (TEPP), came into use in Germany during World War II as an agricultural substitute for nicotine and for possible use as a nerve gas in chemical warfare. TEPP is water-soluble and has a rapid absorption and onset of action by either the oral or dermal routes. It is also the most highly toxic of the organophosphorus insecticides 11 .
Parathion, an organic derivative of phosphoric acid, was recognized shortly after World War II as the most effective of the 50 or more insecticides. Since parathion must first be converted to paraoxon by substitution of oxygen for sulphur to be physiologically active, symptoms from parathion intoxication are often delayed for six to 24 hours. Of the organophosphorus group, parathion is the most common cause of human poisoning and fatality 11 .
Pharmacology
There are more than a hundred organophosphate compounds used regularly and obtaining even clinically relevant data such as the lipid solubility, half-life, conversion to active metabolites, binding to antidotes and whether they are associated with delayed neuropathy or neuropsychiatric effects is difficult or impossible for many of these compounds.
There is an attempt however to classify these compounds based on toxicity and clinical use 11 Organophosphates may also be classified as direct or indirect inhibitors of acetylcholinesterase. Direct acting nerve gases like sarin are readily absorbed and immediate in effect compared to the indirect inhibitors such as parathion, which, as mentioned above, needs to be converted to paraoxon before causing acetylcholinesterase inhibition. This results in delayed onset of action.
Pharmacokinetics
The onset, intensity and duration of the pharmacological effects that occur after poisoning are determined largely by the nature of the particular compound and whether it exhibits reversible or irreversible cholinesterase binding. The degree and route of exposure and the lipid solubility and rate of metabolic degradation are also important ( Table 1) .
Most organophosphates are highly lipid-soluble and are well absorbed from the skin, oral mucous membranes, conjunctiva and gastrointestinal and respiratory routes. The effector organ dysfunction is local at first and rapidly spreads to become generalized. Subsequently most organophosphates are hydrolysed by enzymes, the A esterases or paroxonases, which are not inhibited by OP compounds. These enzymes are found in the plasma and in the hepatic endoplasmic reticulum and split the anhydride P-F, P-CN or ester bonds 12 . The metabolic breakdown products are then excreted in the urine (Figure 1 ). the terminal nerve endings of all post ganglionic parasympathetic nerves and in both sympathetic and parasympathetic ganglia. It is also released at skeletal muscle myoneural junctions and serves as a neurotransmitter in the central nervous system 13 . Acetylcholinesterase is present in two forms: (viz.) true cholinesterase which is found primarily in the nervous tissue and erythrocytes and pseudocholinesterase which is found in the serum and liver 11 . Normally these enzymes hydrolyse acetylcholine into two inactive fragments, acetic acid and choline. Organophosphates bind to the acetylcholinesterases irreversibly and convert them to inactive proteins resulting in the accumulation of acetylcholine at the above-mentioned receptors leading to overstimulation and subsequent disruption of nerve impulse transmission in both the peripheral and central nervous system.
Aetiology of OP Poisoning
Organophosphorus poisoning results either from suicidal or accidental poisoning, or from occupational exposure during farming. A large proportion (68%) present following a suicide attempt 9, 14 . Most patients are young (<30 years) with a male preponderance 14, 15 . Occupational exposure and accidental poisoning accounted for 16.8 and 15.8% respectively 14 .
Clinical Features of Poisoning
Clinical features of acute poisoning occur, almost always, within 24 hours of ingestion/exposure of the organophosphorus compound. It must be remembered that in the initial stages the symptoms and signs may be of a non-specific illness like a gastro-enteritis with vomiting, diarrhoea and abdominal pain. A high index of suspicion is therefore needed to make the diagnosis early.
The clinical features can be broadly classified as secondary to the (a) muscarinic effects, (b) nicotinic effects and (c) central receptor stimulation 16 . The end result may be multi-system manifestations involving the gastrointestinal tract, respiratory system, cardiovascular system, nervous system, skeletal muscles, other organs and metabolic effects such as hypo-or hyperglycemia ( Table 2 ).
NEUROLOGICAL MANIFESTATIONS IN OP POISONING
Much importance has been given to the neurological manifestations in OP poisoning (Table 3 ) as a large number of patients with acute exposure develop neuromuscular weakness requiring prolonged ventilation. Three different types of paralysis are recognized based largely on the time of occurrence and their differing pathophysiology.
Type I Paralysis or Acute Paralysis
This occurs along with the initial cholinergic symptoms. It is postulated to be a result of persistent depolarization at the neuromuscular junction due to 13 
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Anaesthesia and Intensive Care, Vol. 28, No. 1, February 2000 It has been claimed that these manifestations respond to atropine 17 , although one would not anticipate atropine blocking the nicotinic effects of acetylcholine. Paralysis may also involve the respiratory muscles leading to respiratory embarrassment or arrest requiring ventilation. This may be further compounded by the bronchorrhea that predisposes to pneumonia. Acute respiratory failure was observed in 33% of patients who presented with acute organophosphorus poisoning 18 .
Type II Paralysis or Intermediate Syndrome
This was first described in 1974 by Wadia et al 17 as Type II signs and subsequently characterized and termed as "Intermediate Syndrome" by Senanayake 19 . Since then there have been numerous reports of this syndrome [20] [21] [22] [23] [24] . It is a distinct clinical entity that develops after the acute cholinergic crisis and before the expected onset of the delayed neuropathy. This was observed in Senanayake's series of 10 patients who, on recovering from the cholinergic crisis, developed the syndrome 24 to 96 hours after the poisoning. In 70% of patients, respiratory insufficiency drew attention to the onset of the syndrome. Various degrees of cranial nerve palsies and proximal muscle weakness were observed. There was a relative sparing of the distal muscle groups. The reported incidence of this syndrome varies between 8 and 49% [23] [24] [25] .
One of the earliest manifestations in these patients is the presence of marked weakness of neck flexion with inability to lift the neck from the pillow. This is a useful test to assess if a patient is likely to develop respiratory muscle weakness. The usual cranial nerves involved are those supplying the extraocular muscles. Cranial nerves VII and X are less frequently affected. Electromyographic studies suggest a combination of pre-and post-synaptic dysfunction of neuromuscular transmission. Senanayake showed a fade on tetanic stimulation, absence of fade on low-frequency stimulation and absence of post-tetanic facilitation 19 . EMG studies in our cohort of patients have shown that the primary type of involvement is an axonal neuropathy. In addition, neuromuscular transmission defect and anterior horn cell or toxin induced muscular instability also appear to play a role in Type II paralysis (sent for publication). This syndrome persists for about four to 18 days and most patients survive this unless infections or cardiac arrhythmias complicate the course.
Type III Paralysis or Organophosphate-Induced Delayed Polyneuropathy (OPIDP)
OPIDP is a sensory-motor distal axonopathy that usually occurs after ingestion of large doses of certain organophosphate insecticides [26] [27] [28] . Two distinct clinical entities have been described-one being pure motor polyneuropathy and the other being a mild sensory component associated with a severe motor component. A pure sensory neuropathy was not observed in either single or repeated acute OP poisoning 26 . Unlike the Intermediate Syndrome, it usually occurs two to three weeks after the acute poisoning episode and is characterized by distal muscle weakness with relative sparing of the neck muscles, cranial nerves and proximal muscle groups. The EMG feature is suggestive of denervation and recovery is delayed for up to six to 12 months. High-dose methyl prednisolone has been shown to be beneficial in experimental animals 29 .
OTHER NEUROLOGIC MANIFESTATIONS
Various neuropsychiatric manifestations have been described especially in chronic OP poisoning 30 . These have been termed "Chronic Organophosphate Induced Neuropsychiatric Disorder" (COPIND) ( Table 3 ). Extrapyramidal manifestations have also been reported in acute poisoning developing four to 31 . Neuro-ophthalmological sequelae have also been documented in individuals who have been exposed environmentally to OP over long periods of time 32 . Other rarer neurological manifestations include Guillain Barré syndrome 33 , sphincter involvement 34 , isolated bilateral recurrent laryngeal nerve paralysis 35 and ototoxicity 36 .
CARDIOVASCULAR MANIFESTATIONS Cardiac manifestations accompany poisoning with OP compounds and are often the cause of serious complications or fatality. A systematic analysis of 46 patients admitted with organophosphate/carbamate poisoning in Jordan 37 showed a wide variety of cardiac disturbances ( Table 4 ). Ludomirsky et al 38 described three phases of cardiac toxicity after OP poisoning. Phase 1: a brief period of increased sympathetic tone; Phase 2: prolonged period of parasympathetic activity including possible atrioventricular block at this stage and Phase 3: QT prolongation followed by torsade de pointes ventricular tachycardia with subsequent development of ventricular fibrillation. A picture of transient myocardial infarction has also been reported in five of 168 patients with OP poisoning 39 . In a recent study of 223 patients with OP poisoning, QTc prolongation at admission was found to be associated with respiratory failure and a higher mortality 40 .
The mechanism of cardiac toxicity is unclear. Various postulates include (a) direct toxic effect of the compound on the myocardium, (b) overactivity of cholinergic or nicotinic receptors causing haemodynamic alterations, (c) hypoxaemia, (d) acidosis, (e) electrolyte abnormalities and (f) high-dose atropine therapy.
RESPIRATORY MANIFESTATIONS
Muscarinic, nicotinic and central effects all contribute to the respiratory manifestations in acute OP poisoning. In the acute phase, the muscarinic effects of bronchorrhea, rhinorrhea, bronchospasm and laryngeal spasm can result in airway obstruction. The nicotinic effects lead to weakness and paralysis of the muscles of respiration as well as the oropharyngeal muscles. Finally central depression of respiration leads to cessation of respiration. This is thought to be due to involvement of cholinergic systems in the brainstem 18 .
Acute (<24 hours) respiratory failure defined as respiratory distress, P a O 2 <50 to 60 mmHg and a P a CO 2 >50 to 55 mmHg accompanied by acidaemia (pH <7.30), was seen in 35 of 107 patients (33%) with acute OP and carbamate poisoning 18 . Most patients with Intermediate Syndrome develop respiratory failure which requires ventilation 18, 19 .
GASTRO-INTESTINAL MANIFESTATIONS
These manifestations (Table 2) are the first to occur after oral ingestion of OP compound. They respond well to atropine therapy. Rarely acute pancreatitis has been observed with organophosphorus poisoning [41] [42] . Patients may also have features of hypoor hyperglycaemia [43] [44] [45] .
GRADING SEVERITY OF OP POISONING
Various attempts have been made to grade the severity of poisoning [46] [47] . We have found however, that these do not necessarily correlate with outcomes with some patients appearing to recover in 24 hours but later developing Intermediate Syndrome.
DIAGNOSIS
The diagnosis of OP poisoning is made largely on a history of exposure and a combination of clinical features such as altered neurological state, tachycardia or bradycardia, altered pupils (usually pinpoint), excessive salivation, bronchorrhea and sweating with the typical odour of an insecticide. Muscle fasciculations may be present at the time of presentation. It should be remembered that some patients might present primarily with nicotinic effects of tachycardia and mydriasis rather than the anticipated bradycardia and miosis. Treatment is initiated immediately without waiting for the blood investigations. Investigations are essentially to confirm the diagnosis and to rule out multiple poisonings and other metabolic causes of altered neurological state. Efforts should also be undertaken to deliver the ingested solutions to the hospital for identification. 15 
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Cholinesterase estimation
Both true and pseudocholinesterase levels can be estimated to assess poisoning. These levels are markedly reduced in OP poisoning. While true cholinesterase levels correlate with severity at presentation, pseudocholinesterase levels do not 48 . Furthermore, serial cholinesterase levels do not correlate with clinical improvement and hence these tests are to be used primarily to confirm the diagnosis of OP poisoning. Other causes of low serum cholinesterase levels include parenchymal liver disease, congestive cardiac failure with hepatomegaly, metastatic carcinoma, malnutrition, dermatomyositis and acute infection. A 25% or greater depression in RBC cholinesterase level is taken as a true indicator of OP poisoning 11 .
MANAGEMENT

General measures Decontamination
Skin decontamination is a very important step that should never be neglected or hurried. The patient should be stripped and washed thoroughly initially with soap and water and subsequently with ethyl alcohol. This is to prevent further absorption through the skin. Care should be taken by the health personnel to avoid contamination while handling these patients. Protective clothing and glasses should be worn.
Gastric decontamination should be performed by forced emesis if the patient is awake, or through a gastric lavage. Patients should receive activated charcoal 0.5 to 1.0 g/kg every four hours to promote adsorption in the gastrointestinal tract. Sodium sulphate or sorbitol can be used as a cathartic. Recent studies have shown that the addition of serotonin adipinate (a drug which enhances the propulsive function of the gastrointestinal tract) resulted in a shortening of the toxicogenic phase of poisoning with a 3.5 fold reduction in mortality 49 .
Airway and Respiration
The airway should be secured and adequate oxygenation ensured. This is important as atropine can precipitate ventricular fibrillation in hypoxic patients. On the other hand, early use of adequate doses of atropine will dry respiratory secretions, improve muscle weakness and thereby improve oxygenation. Since these patients are prone to respiratory failure both during the acute phase and the Intermediate Syndrome, careful observation of respiratory status is required. The following can be monitored on a regular basis to assess progression:
(a) symptoms of ocular muscle involvement (e.g., diplopia), (b) neck muscle weakness, (c) respiratory rate, (d) tidal volume/vital capacity, (e) single breath count and (f) arterial blood gas estimation. In addition, these patients may develop pneumonia which should be anticipated and treated appropriately. Theophylline is considered contraindicated in the management of OP poisoning 11 .
Cardiac monitoring
As mentioned earlier, a wide range of cardiac manifestations occur and careful hemodynamic and electrocardiac monitoring should be undertaken on all patients. It should be remembered that various factors such as hypoxaemia and electrolyte abnormalities contribute to the cardiovascular complications. Some of the cardiac manifestations revert with atropine therapy. In cases of ventricular tachycardia associated with a prolonged QTc, electrical pacing is the treatment of choice 3 .
Specific Therapy Anticholinergic agents
Treatment with anticholinergics is still the mainstay of treatment and should be started as soon as the airway has been secured. It is recommended that atropine be started initially as a 2 mg IV bolus and subsequently at doses of 2 to 5 mg every 5 to 15 minutes until atropinization is achieved. In children the initial dose of atropine is 0.05 mg/kg IV with a maintenance dose ranging from 0.02 to 0.05 mg/kg 11 . To prevent atropine toxicity it is important to monitor these patients closely and have clear end-points for atropinization. Contrary to earlier beliefs, it is no longer necessary to achieve total atropinization (i.e., to achieve full mydriasis, heart rate >150/min and absent bowel sounds). In our experience, a dose required to keep heart rate above 100/min, pupils mid size and with bowel sounds just present, keeps the patient adequately atropinized without the attendant risks of hyperexcitability, restlessness, hyperpyrexia and cardiac complications that are seen with total atropinization. Some uncontrolled studies have shown that atropine infusion as opposed to bolus doses at regular intervals reduces mortality 50 . Others such as Bardin et al have demonstrated that glycopyrrolate is equally effective with less central nervous system side-effects and better control of secretions 47 . The dose of atropine required is maximal on day 1 and tends to decrease over the next few days. The mean total requirement of atropine in our series has been 140 to 167 mg 51 . Atropine however does not reverse the effects on the skeletal muscle.
Oximes
Oximes are nucleophilic agents that re-activate the phosphorylated acetylcholinesterase by binding to the organophosphorus molecule 12 . The use of oximes in acute OP poisoning has been a controversial subject for the last two decades. There have been very few randomized controlled trials that have addressed the role of pralidoxime (P2AM) in the management of patients with OP poisoning.
Initial uncontrolled studies suggested that P2AM was useful in the routine management of OP poisoning 52, 53 . A subsequent report by de Silva et al 54 , studying two periods of time (one when P2AM was available in their country and another when it was unavailable), found that P2AM did not make any difference to the outcomes. Other uncontrolled studies also suggested that P2AM was not useful 46, 55 .
In a more recent study on the effect of oximes on nerve agents and pesticide poisoning 56 , the authors found that respiratory complications were more common in the group treated with obidoxime or P2AM. Mortality was 9% (4/43) in the group treated with atropine, 50% (6/12) in the group treated with obidoxime and atropine and there was no mortality in the group treated with P2AM (eight patients).
Since one of the major criticisms in some of the studies was that an inadequate dose was used, two major randomized controlled trials were done using high dose P2AM (12 g over a period of three days). It was found that a higher mortality was observed in the P2AM group 5, 51, 57 . Ventilatory requirements and the incidence of Intermediate Syndrome were also higher in the P2AM treated group (Table 5 ). These studies concluded that high dose P2AM has no role in the routine management of patients with OP poisoning.
The above evidence seems to suggest that respiratory complications and probably mortality are higher when high dose oximes are used in the management of organophosphorus poisoning. Scott 58 reported repeated asystole following P2AM in organophosphate poisoning. Therefore it appears that high-dose P2AM may be harmful, especially as high-dose oximes in themselves can produce muscle weakness 59 . A lower dose (an ideal dose not yet assessed) given early in the course of illness may be beneficial (Table 6 ) and studies are currently underway to assess the role of low-dose P2AM (1.0 g) in OP poisoning.
There is a preliminary report that suggests that there were electrophysiological improvements when obidoxime was administered within 12 hours of poisoning although evidence of acetylcholinesterase inhibition did not subside completely. These improvements were minimal or absent when therapy was delayed 26 hours or more 60 . It is also possible that the response to P2AM may be different for the "direct" acetylcholinesterase agents as opposed to the "indirect" acetylcholinesterase agents and this aspect also warrants further study.
CARBAMATE INSECTICIDES
The carbamates are a group of insecticides derived from carbamic acid. They have a broad spectrum of use as agricultural and household garden insecticides. The carbamate group in contrast to the organophosphate group causes reversible binding to acetylcholinesterase.
The carbamates are absorbed by all routes including inhalation, ingestion and dermal absorption. A wide variety of compounds are commonly available. Of these Aldicarb is considered the most toxic as it is 17 
ORGANIC INSECTICIDES
Anaesthesia and Intensive Care, Vol. 28, No. 1, February 2000 a systemic insecticide and is taken up from the soil and incorporated into plants and fruits 11 .
The clinical presentation of carbamate poisoning is very similar to that of organophosphates but usually of shorter duration and lesser severity. This is due to a process of spontaneous decarbamylation during which the active enzyme is regenerated. Recovery from carbamate poisoning takes place usually within 24 hours, depending on the severity of poisoning. This corresponds with plasma elimination half-lives ranging between 45 and 120 minutes for human dimethyl carbamyl enzyme and 20 and 55 minutes for physostigmine which produces a mono-methyl carbamyl enzyme 61 . The differences between organophosphorus and carbamate poisoning are summarized in Table 7 .
Mortality with pure organocarbamate poisoning is rare. The 1987 Annual report of the AAPCC National Data Collection System reported 4458 exposures to carbamate insecticide with 905 patients treated at a health centre facility but no deaths 62 . The outcome in children with carbamate poisoning is similar 61 .
Therapy
The treatment of carbamate poisoning is similar to that of OP poisoning and includes (a) decontamination, (b) protection of airways, (c) cardiac monitoring and (d) specific therapy.
Atropine is the agent of choice for carbamate poisoning. Unlike OP poisoning, these patients require a much smaller dose for atropinization and for a shorter duration (less than 24 hours). P2AM is not indicated in carbamate poisoning in view of the fact that the inhibition of acetylcholinesterase is reversible. Studies suggest that P2AM is not harmful 61 .
ORGANOCHLORIDE INSECTICIDES
Organochloride compounds are a distinct group of organic insecticides that are highly toxic and act predominantly as central nervous system stimulants. They are soluble in fat but not soluble in water. The toxicity of these compounds is compounded by the fact that they persist in the body for protracted periods of time and also the solvents in which they are mixed are themselves toxic 63 . This group of compounds has been largely banned in the United States after the startling observation that they were present in virtually everyone in the general population. Some of these have also been shown to predispose to malignancy in experimental animals 11 .
The organochlorides have been broadly classified into the following 63 : (a) halobenzene derivatives and analogs, e.g., DDT, chlorbenzilate, kelthane, methoxychlor. (b) benzene hexachloride, e.g., lindane (c) chlorinated camphenes, e.g., toxaphene (d) polycyclic chlorinated insecticides, e.g., chlordane, heptachlor, aldrin, enderin. Poisoning with organochloride compounds is uncommon. Clinically they present with gastrointestinal symptoms (e.g., vomiting), followed by CNS manifestations, in particular, seizures 64 . In the case of chlorinated camphenes, the initial sign of poisoning may in fact be a seizure 63 . Other neurologic manifestations such as higher function disturbances and cognitive dysfunction may also occur 65 . Leucocyte function abnormalities have been reported in occupational exposure 66 while hepatic and renal dysfunction has been demonstrated in experimental animals 63 .
Management
Therapy for all groups of chlorides is similar and includes decontamination and supportive therapy. It must be remembered that oils and fats should not be used during skin decontamination as these compounds are highly lipid soluble 11 . Supportive therapy includes respiratory support and control of seizures with benzodiazepines.
Course
Recovery is slow and protracted if the compound has been mixed with an organic solvent and ingested, and also if the patient has had convulsions. In the case of lindane poisoning, the occurrence of pulmonary oedema or vascular collapse is a poor prognostic feature. The toxicity of the polycyclic compounds is greatly increased in the presence of liver damage 63 . 
PYRETHROIDS
The insecticidal properties of Chrysanthemum cinariaefolium have been known from ancient times. These flowers contain pyrethrins that are naturally occurring insecticidal agents. Their use as insecticides has however been limited by their susceptibility to photolysis. The first synthetic pyrethroid was developed in the late 1940s but it was not until 1973 that the first photostable pyrethroid was synthesized. In comparison with the other organic insecticides, synthetic pyrethroids have a high insecticidal activity on a weight per activity basis. In contrast, they have a low toxic effect on mammals through the oral and intraperitoneal routes as they are rapidly metabolized and leave virtually no residue. These are used to control a wide variety of agricultural insects, insect vectors of disease and to eliminate veterinary pests by topical application 67 .
Chemistry
Pyrethrium contains two active components that are extracted from the pyrethrium flowers: pyrethrin I, which is the most active ingredient for killing and pyrethrin II for rapid insect knock-down 68 .
Mechanism of Action
Pyrethroids act primarily on the sodium channels. In crayfish it causes repetitive discharges in response to a single stimulus. This is thought to be due to a slowing of the sodium channel kinetics resulting in prolonged sodium current following the normal peak sodium current. A kinetic model has also been proposed to account for the action of pyrethroids in which the pyrethroid molecule binds to the sodium channels, at both closed and open states to produce a modified open state 69 .
Manifestations
Two types of manifestations have been reported in experimental animals 67 . Type I pyrethroid poisoning in mice and rats produces a syndrome characteristized by prostration, altered startle reflexes and whole body tremors (referred to as tremor or "T syndrome"). This effect is mediated by repetitive stimulation of axonal sodium channels. Type II pyrethroid poisoning in mice and rats causes ataxia, convulsions, hyperactivity, choreoathetosis and profuse salivation (referred to as choreoathetosis/salivation or "CS syndrome"). Type II symptoms are peculiar to compounds containing alpha cyano substitutent (deltamethrin and fenvalerate) and involve GABA receptor/ionophore complex.
Poisoning
There have been very few cases of pyrethroid poisoning documented in literature. Chen et al 70 , reported adverse effects in 26.8% of people involved in spraying. This included symptoms of abnormal facial sensation, dizziness, headache, fatigue, nausea, loss of appetite and muscular fasciculations. Knox et al 71 reported paraesthesia after topical application of fenvalerate lasting 24 hours. Lessenger 72 reported shortness of breath, nausea, headache and irritability in five office workers who accidentally inhaled cypermethrin. In our series 73 , there were five cases of suicidial poisoning. Vomiting was present in four patients, excessive salivation in one patient, drowsiness in three patients and convulsions in one patient. High sodium levels were observed in two patients ( Table 8 ). One patient died within 48 hours of admission after suffering convulsions and then developing multi-system organ failure which was refractory to treatment.
Treatment
The excellent safety record of pyrethroids is partially responsible for the limited effort invested in the search for effective antidotes. Atropine blocks salivation in rats produced by cypermethrin but does not prevent the dramatic increase in cGMP levels in cerebellum. The lethal dose is unaltered in mice treated with atropine. The centrally acting drug, mephenesin, protects rats from deltamethrin toxicity but only in high doses that cause profound muscle relaxation. Pretreatment with diazepam delays onset of symptoms in mice with Type II syndrome 74 . 19 
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